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Squamous cell cancer of the head and neck (SCCHN) is a disease
associated with major morbidity and mortality. It is the fifth most
common cancer worldwide and the incidence of SCCHN is
increasing in developing countries (Macfarlane et al, 1994; Parkin
et al, 1985). The epidemiology of SCCHN is complex due to the
multigenic nature of the disease and the number of potential envi-
ronmental agents to which individuals may have been exposed. It
is clear that the major aetiological agents are tobacco and alcohol
exposure (Maier et al, 1992; Vokes et al, 1993). Alcohol and
tobacco exposure increase the risk of SCCHN in a dose-dependent
and independent manner. Other risk factors include nutrition,
occupation, viral infection and poor dentition (Maier et al, 1991;
Muscat and Wynder, 1992). These risk factors do not, however,
adequately explain all cancer cases. Until recently, little attention
has been paid to possible hereditary factors in SCCHN. However,
3 recent case–control studies have shown a relative risk (RR) for
SCCHN of 3.5–3.8 in association with a family history of cancer
of the upper aerodigestive tract (UADT) and/or lung cancer
(Copper et al, 1995; Foulkes et al, 1995, 1996). 
Despite therapeutic advances in the treatment of SCCHN, the
overall survival from the disease has remained unchanged over the
last 20 years. A contributory factor to this is that patients with
successfully treated early-stage SCCHN have a high incidence of
second primary cancers of SCCHN or UADT (Day and Blot,
1992). Generally, the presence of multiple primary cancers in an
individual is a sign that there may be an increased hereditary
predisposition to cancer in that person. Inter-individual differences
in susceptibility to second tumours could be accounted for by
genetic factors (Trizna and Schantz, 1992; Bongers et al, 1996).
Individuals with a second primary SCCHN are more likely to have
a family history of SCCHN than those with only single primaries
(Bongers et al, 1996; Foulkes et al, 1996; Morita et al, 1998). 
The tumour suppressor gene CDKN2A (also known as p16) is
localized on chromosome 9p21 and is thought to play an important
role in the development of some cancers. The gene consists of 3
coding exons, exon 1 (125 bp), exon 2 (307 bp) and exon 3 (12 bp)
(Kamb et al, 1994a). It encodes a 16 kDa protein that binds to
cyclin-dependent kinase (cdk) 4 and 6 inhibiting their association
with cyclin D1 (Serrano et al, 1993). The inhibition of the cyclin
D1-cdk4/6 complex activity prevents retinoblastoma protein phos-
phorylation, which normally leads to the arrest of the cell cycle in
the G1/S transition (Serrano et al, 1993). Somatic CDKN2A dele-
tions have been documented in melanoma, oesophageal, lung and
bladder cancer (Kamb et al, 1994b). Germline CDKN2A mutations
have been shown to predispose to familial melanoma (Hussussian
et al, 1994; Kamb et al, 1994b). CDKN2A is thought to be an
important tumour suppressor gene in the aetiology of SCCHN.
Somatic mutations occur in 10% of SCCHN and homozygous dele-
tions occur in approximately 50% (Reed et al, 1996). Inactivation
of CDKN2A is thought to be an early event in the development of
SCCHN. In families with familial melanoma, an association has
been reported with SCCHN and pancreatic carcinoma (Whelan et
al, 1995). In one study of 67 cancer prone families, a germ-line
mutation in CDKN2A (M531) was identified in a woman with
multiple primary tumours, including SCCHN. Her grandmother
was reported to have an oral canncer (Sun et al, 1997).
The aim of this study was to investigate whether germline
CDKN2A mutations contributed to the postulated increased
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an index SCCHN followed by a second cancer. 
MATERIALS AND METHODS 
Patient selection 
Individuals with index SCCHN who had developed a second
primary cancer in accordance with the criteria defined by Hong
et al (1990) were identified for the study. An SPT is defined as
occurring more than 3 years from the original diagnosis or is sepa-
rated by greater than 2 cm of entirely normal epithelium. If the
SPT occurs in the lung it must be solitary and occur greater than 3
years from the original diagnosis. If an SPT is of different
histology these criteria do not apply. An SPT can occur anywhere
and is not just limited to the UADT. Venous blood samples in
EDTA were obtained from 40 patients with histologically proven
SCCHN and an SPT. The patients were participants in a multi-
centre molecular epidemiology study assessing the possible under-
lying genetic mechanisms in head and neck cancer. Clinical and
epidemiological characteristics were recorded. A detailed first-
degree family history pedigree was obtained from each partici-
pant. All blood samples were obtained with written informed
consent and ethical approval from participating centres. 
Patient characteristics 
24 of the patients were male and 16 female. The mean age at initial
presentation was 61.3 years (+/–9.8). All had histologically proven
SCCHN as an index tumour. The predominant primary site was
oral cavity (22 patients) followed by larynx (12), hypopharynx (4)
and oropharynx (2). Of the second cancers, 24 were SCCHN, 7
prostate adenocarcinoma, 3 lung SCC, 2 oesophageal SCC, 2
melanoma, 1 colon adenocarcinoma and 1 chronic granulocytic
leukaemia. 3 patients had 3 primaries in total; 2 had further SCCHN
and 1 developed adenocarcinoma of the lung. 
DNA extraction 
Peripheral blood samples (20 ml) were collected from 40 patients
with SPT and stored in EDTA at –70˚C. DNA extraction was
undertaken by the method of Kunkel et al (1977) with some modi-
fications. 4 volumes of water were initially added to whole blood.
The phenol-chloroform extraction step was not included and the
salting out procedure of Miller et al (1988) was used to clean and
retrieve the DNA. DNA was washed in 70% alcohol and dried
before dissolving in 0.3 ml of water. 
Polymerase chain reaction (PCR) 
Sample DNA was added to a reaction mix containing 10X buffer
(Perkin Elmer), 1.5 mmol MgCl2 for exon 1 and 2, 1.25 mmol for
exon 3, 0.8 mM dNTPs, 1.0 µ M primer and 0.4 µ l of AmpliTaq
Gold (Perkin Elmer), and 5% DMSO. The primer sequences used
were as described by Kamb et al (1994b) and Hussussian et al
(1994). The total reaction was made up to 50 µ l with water. The
tubes were topped with mineral oil (Sigma) and cycled in a Hybaid
thermocycler. Thermocycling for exon 1 and 2 was 95˚C for 9
min; 94˚C for 1 min, 60–55˚C for 1 min touchdown, 72˚C for 1
min – 11 cycles; 94˚C for 1 min, 55˚C for 1 min, 72˚C for 1 min – 25
cycles; 72˚C for 10 min. Thermocycling for exon 3 was 95˚C for 5
min; 95˚C for 1 min, 55–50˚C for 1 min touchdown, 72˚C for 1
min – 11 cycles; 95˚C for 1 min, 50˚C for 1 min, 72˚C for 1
min – 34 cycles; 72˚C for 10 min (adapted from Harland et al
1997). A 5 µ l aliquot of PCR reaction mix was run on 2% agarose
gel to check for presence of the required product. PCR products
were purified before dye terminator sequencing according to
Hamoudi et al 1996. The DNA was dissolved in 15 µ l of water and
an aliquot was run on 2% agarose gel to check presence and purity
of the product. A positive control was included in the sample set, a
known mutation in exon 3 (supplied by Harland et al, 1997). 
Cycle sequencing 
PCR products were sequenced directly using an ABI prism dye
terminator cycle sequencing reaction kit. Thermocycling was 96˚C
for 1 min; 96˚C for 30 s, 50˚C for 15 s, 60˚C for 60 s for 25 cycles.
The extension products were added to 3 M sodium acetate, precip-
itated with absolute alcohol and centrifuged. The pellet was
washed with 70% alcohol, dried and then stored at –20˚C. 
Automated sequencing 
Exons 1, 2 and 3 of CDKN2A were sequenced in both the forward
and reverse direction. Sequencing was conducted on a 6% poly-
acrylamide denaturing gel in a 1X TBE (Tris borate buffer) using
an ABI 377 automated flourescent DNA sequencer. The DNA
pellet was dissolved in 4 µ l of formamide and loading dye. The
data were stored using DNA Sequencing Analysis Software. On
completion of the run the data were analysed using Sequence
Navigator software (ABI). 
RESULTS AND DISCUSSION 
Evidence is increasing that inter-individual differences in cancer
susceptibility may be genetically determined. This genetic compo-
nent in diseases such as SCCHN is likely to be multifactorial and
will include alterations in germline tumour suppressor genes,
metabolic enzyme function and DNA repair mechanisms. Second
primary tumours occur in 10–30% of patients with SCCHN
(Franco et al, 1991). As second or multiple primary tumours are
associated with several of the hereditary cancer syndromes,
Li–Fraumeni syndrome, Bloom syndrome and Fanconi anaemia,
(Trizna and Schantz, 1992) and family studies have demonstrated
an increased risk of SCCHN amongst relatives of patients with
SPT (Bongers et al, 1996; Foulkes et al, 1996; Morita et al, 1998)
we assessed the possible role of germline CDKN2A mutations in
the development of SPT. 
Further support for this hypothesis is that CDKN2A alterations
are common in human cancer and high frequencies of somatic
homozygous deletions and mutations are seen in SCCHN (Reed
et al, 1996; Miracca et al, 1999). Melanoma kindreds with
CDKN2A mutations have also been described with cases of
SCCHN (Lynch et al, 1981; Whelan et al, 1995; Yarborough et al,
1996). We screened the full coding sequence of CDKN2A for
germline mutations in 40 patients with index SCCHN and an SPT.
No mutations were identified within the coding region of the gene
(incidence 0%: 95% CI 0–8%). A control mutation in exon 3 was
detected. One patient was found to have a c→ g transition (+32),
not previously described, in exon 3. These results suggest that
germline mutations in CDKN2A do not contribute to the increased
cancer susceptibility in this group. 
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study. In the methodology used, we cannot exclude the possibility
that we may have missed a small number of mutations within the
CDKN2A gene. We would also not have detected changes in the
promoter region or introns of CDKN2A, which in some way might
abrogate the function of the gene. Germline mutations in CDKN2A
are responsible for the predisposition to melanoma in some fami-
lies, but not all families that demonstrate 9p21 linkage are found to
have mutations. 2 studies of mutation-negative families have
demonstrated a 5′  UTR variant (G-34T) which creates an aberrant
initiation codon (Liu et al, 1999; Harland et al, 2000). This alter-
ation and other non-coding mutations may be important in a small
percentage of families. 
The selection of patients may have led to a number of factors
that could have obscured an underlying genetic effect. Patients
were identified for this study who had developed index SCHNN
and then an SPT. This resulted in a heterogeneous population in
terms of the primary site within the head and neck and subsequent
site of the second primary cancer. It is known that younger age of
onset of cancer may be associated with an underlying genetic
predisposition. However, in this study the average age of develop-
ment of SCCHN was 61.3 years (+/–9.8 years), which was not
lower than observed in a series of single incident cases of SCCHN
(62.2 years: SD +/– 13) (data not shown). A family history of
cancer is also a marker for possible genetic predisposition. 27
patients had a family history of cancer of which 4 had a relative
with SCCHN (Table 1). The male–female ratio was 3:2, which is a
higher proportion of females than would be expected in incident
single SCCHN, and may reflect gender-based differences in
predisposition to second cancers. 
The definition of second primary tumours in this study was
based on the clinical definition defined by Hong et al (1990). It is
likely that some of the patients included in this study had in fact
developed a metastasis from their index tumour, and are not genet-
ically predisposed to SPT. Molecular studies have demonstrated
solitary lung tumours to be metastases rather than new primaries
(Leong et al, 1998) and similarly synchronous and metachronous
lesions have been shown to be genetically identical (Worsham
et al, 1995; Bedi et al, 1996; Scholes et al, 1998). Results from
molecular studies may be incorporated in the definition of SPT in
the future. 
Other studies assessing patients with multiple primary tumours
have been successful in demonstrating germline mutations of
tumour suppressor genes. Germline p53 has been identified in
patients with multiple primary tumours and members of cancer-
prone families (Wang et al, 1996). Gallo et al (1999) screened 24
consecutive patients with index SCCHN and SPT for p53 muta-
tions. p53 germline mutations were identified in the peripheral
blood and cancers of 3 patients, 1 was a missense mutation in exon
6 and the other 2 were same-sense polymorphisms with no change
in the amino acid sequence of the p53 protein. Abnormal expres-
sion of wild-type p53 protein was seen in normal and pathological
tissue from the 2 patients with the p53 polymorphisms. 
Another tumour suppressor gene that has been assessed in
SCCHN is the BRCA2 gene. Easton et al (1997) reported an excess
of laryngeal cancer (relative risk = 7.67) in a large hereditary
breast cancer family. A significant number of cancers of the buccal
cavity and pharynx were observed in a study examining a large
series of BRCA2 families from North America and Europe (RR =
2.26;  P = 0.03) (Breast Cancer Linkage Consortium, 1999).
Cancers of the throat and oral cavity were also observed in BRCA2
carriers in 3 out of 17 French Canadian breast cancer families
(Tonin et al, 1998). Hamel et al (1999) assessed 78 cases of
SCCHN for founder mutations in BRCA2 (53 were French
Canadian; 25 Ashkenazi Jewish cases). No founder BRCA2 muta-
tions were observed and therefore the study concluded that
screening for BRCA2-inherited mutations, as a risk factor for
SCCHN, is not warranted. 
Although mutations in the CDKN2A gene have been reported in
kindreds with oral cancer and familial melanoma, we have failed
to demonstrate any coding germline CDKN24 mutations in 40
patients presenting with index SCCHN and subsequent second
primary tumours. Other mechanisms that may increase cancer
susceptibility in this group, such as metabolic enzyme polymor-
phisms and DNA repair enzyme polymorphisms and their relation-
ship with smoking and alcohol exposure are currently being
explored. 
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